引用次数
引用: 28,310
H-指数: 49
I10-指数 : 90
出版物: 231
Early closure of clinical trials: The experience of the National Cancer Institute of Canada Clinical Trials Group
W. Parulekar , J. L. Pater
Journal of Clinical Oncology 24 6053 -6053
2
2006
227 Electronic submission and review of radiotherapy planning data for NCIC CTG protocols
C. Field , W. Parulekar , E. Elliott , S. Hunt
Radiotherapy and Oncology 78
2006
Intergroup randomized phase III study of androgen deprivation therapy (ADT) plus radiation therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633).
P. R. Warde , M. D. Mason , M. R. Sydes , M. K. Gospodarowicz
Journal of Clinical Oncology 28
30
2010
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.
R. Yerushalmi , B. Dong , J. W. Chapman , P. E. Goss
Journal of Clinical Oncology 29 513 -513
1
2011
Intergroup Randomized Phase 3 Study of Androgen Deprivation Therapy (ADT) + Radiation Therapy (RT) in Locally Advanced Prostate Cancer (CaP) (NCIC-CTG, SWOG, MRC-UK, and INT: T94-0110; NCT00002633)
M.D. Mason , P.R. Warde , M.R. Sydes , M.K. Gospodarowicz
International Journal of Radiation Oncology Biology Physics 78 ( 3)
6
2010
Comorbidity, age and overall survival in patients with advanced pancreatic cancer – Results from NCIC CTG PA.3: A phase III trial of gemcitabine plus erlotinib or placebo
M.M. Vickers , E.D. Powell , T.R. Asmis , D.J. Jonker
European Journal of Cancer 48 ( 10) 1434 -1442
47
2012
Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer
J.-A. W. Chapman , D. Meng , L. Shepherd , W. Parulekar
Journal of the National Cancer Institute 100 ( 4) 252 -260
136
2008
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)
W. Xie , C. Sweeney , M. Regan , M. Nakabayashi
Annals of Oncology 27
6
2016
The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3
M. J. Moore , G. da Cunha Santos , S. Kamel-Reid , K. Chin
Journal of Clinical Oncology 25 ( 18_suppl) 4521 -4521
19
2007
Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients
J. Chapman , D. Meng , L. Shepherd , W. Parulekar
Journal of Clinical Oncology 25 540 -540
1
2007
Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory Prostate cancer and pain
D.S. Ernst , I.F. Tannock , E.W. Winquist , P.M. Venner
Journal of Clinical Oncology 21 ( 17) 3335 -3342
229
2003
An Analysis of the Real Time Radiotherapy Review Process in an International Phase III Study: MA.20
T.M. Niazi , E. Elliott , I. Olivotto , I. Ackerman
International Journal of Radiation Oncology*Biology*Physics 69 ( 3) S183
2007
CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases.
A. Sahgal , S.D. Myrehaug , S. Siva , L. Masucci
International Journal of Radiation Oncology Biology Physics 108 ( 5) 1397 -1398
6
2020
A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).
W. Parulekar , B. E. Chen , C. Elliott , L. E. Shepherd
Journal of Clinical Oncology 29
7
2011
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).
W. Parulekar , J. W. Chapman , S. Aparicio , Y. Murray
Journal of Clinical Oncology 29
3
2011
NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.
T. J. Whelan , I. Olivotto , I. Ackerman , J. W. Chapman
Journal of Clinical Oncology 29
233
2011
HN5: A phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN.
D. Soulieres , B. Fortin , E. Winquist , D. Charpentier
Journal of Clinical Oncology 28 5562 -5562
2
2010
Abstract PD1-10: Randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced/metastatic breast cancer: CCTG MA38 (NCT02630693)
WR Parulekar , AA Joy , K Gelmon , M Mates
Cancer Research 79
4
2019
Abstract P1-09-08: Predictive effect of cytotoxic tumor infiltrating lymphocytes in HER2-positive metastatic breast cancer: A correlative study with CCTG MA.31
S Liu , B Chen , S Burugu , S Leung
Cancer Research 77
2017
Abstract P6-07-06: Effect of serum biomarkers (activin A, CAIX, HER2, TIMP-1, and uPA) on outcome in HER2+ metastatic breast cancer patients treated in first line with lapatinib or trastuzumab combined with taxane: CCTG MA.31
A Kang , M Hupp , D Ho , J Huang
Cancer Research 77
2
2017